^
Association details:
| Biomarker: | AR W741L |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | bicalutamide (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Novel Mutations of Androgen Receptor A Possible Mechanism of Bicalutamide Withdrawal Syndrome
Excerpt:
Transactivation assays showed that bicalutamide worked as an agonist for both W741C and W741L mutant ARs...In summary, we demonstrate for the first time that within only 6–13 weeks of in vitro exposure to bicalutamide, LNCaP-FGC cells, whose growth had initially been suppressed, came to use bicalutamide as an AR agonist via W741 AR mutation to survive.
